Abiomed, inc. (ABMD)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10
Operating activities:
Net income

31,798

69,217

13,071

88,923

73,960

44,863

50,127

90,066

36,847

13,446

24,503

37,374

14,899

15,432

8,875

12,910

10,998

10,555

7,735

8,859

98,874

12,684

3,839

-1,709

3,622

4,393

1,059

-1,723

3,742

2,684

5,469

3,119

2,567

2,921

601

-4,594

-1,772

-802

-3,201

-5,980

Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation expense

6,003

5,375

4,687

4,365

4,185

3,589

3,388

2,959

2,905

2,780

2,857

2,463

1,714

1,530

1,552

1,406

1,063

862

689

663

974

600

575

621

645

541

670

652

637

637

607

842

1,253

958

1,079

1,046

940

904

1,145

959

Bad debt expense (recovery)

246

89

173

-21

142

111

279

188

46

46

-12

-42

171

1

18

-31

-36

96

19

-37

-48

16

-4

31

36

-4

0

15

-9

36

-2

8

45

7

50

15

7

5

74

53

Stock-based compensation

2,762

10,574

13,324

13,121

10,737

15,578

15,934

12,245

11,183

11,232

9,282

8,656

8,345

6,474

9,650

8,397

7,322

6,139

10,793

4,799

3,824

4,382

4,024

4,290

2,851

1,648

2,798

3,921

2,602

1,936

2,284

2,679

1,869

1,773

1,799

2,332

1,403

1,272

1,375

1,371

Write-down of inventory and other

265

1,827

898

1,259

1,100

1,419

836

897

734

684

2,018

510

1,026

705

646

708

738

404

653

299

1,096

576

353

206

1,371

104

330

207

281

293

346

252

741

716

220

156

401

1,016

741

623

Accretion on marketable securities

53

402

970

1,306

1,100

796

485

363

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of other investments

-22,591

23,350

-45,597

39,654

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Excess tax benefit from stock-based awards

-

-

-

-

-

-

-

-

-

-

-

-

7,443

964

2,590

1,041

3,079

105

302

81

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on disposal of fixed assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-24

0

0

-5

Deferred tax provision

2,402

20,356

-581

10,776

18,247

19,684

-1,213

-44,463

7,884

31,667

6,903

-3,830

6,986

9,040

2,777

7,000

4,914

6,579

4,998

5,805

-87,769

225

225

225

181

226

227

226

210

228

227

90

234

234

225

96

242

243

242

243

Change in fair value of contingent consideration

-1,440

204

305

356

-1,008

90

162

-159

67

588

417

265

978

426

10

176

171

575

156

151

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other non-cash operating activities

941

990

1,174

1,003

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on sale of WorldHeart common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

217

239

Changes in assets and liabilities:
Accounts receivable

-15,884

6,505

8,629

-4,801

2,755

14,137

7,061

-1,930

4,947

7,518

3,619

-795

3,995

3,748

5,324

-1,517

5,846

-130

2,758

2,456

3,650

5,428

440

-1,548

1,435

1,789

59

-1,971

3,075

1,117

426

-2,032

3,160

1,889

1,082

-847

2,416

-2,075

2,349

-767

Inventories

-24

1,057

4,965

7,239

10,659

9,772

8,956

7,794

3,712

6,611

4,061

1,302

3,669

2,331

2,891

3,393

1,381

3,237

2,306

4,549

3,385

2,929

419

234

553

-807

-813

1,689

417

690

2,226

1,982

2,192

1,475

961

1,601

844

1,115

194

-645

Prepaid expenses and other assets

1,083

173

660

3,417

3,205

-2,665

-144

2,131

3,433

164

-46

915

-1,557

1,894

2,036

-7

2,633

113

7

-463

1,299

41

-116

255

694

-417

1,054

-292

685

-452

28

65

310

43

106

-220

627

-321

-175

-292

Accounts payable

1,740

60

2,244

-1,463

3,067

4,148

-1,923

2,684

1,817

2,296

4,690

-4,391

4,023

1,636

2,051

-145

-905

77

-50

-1,767

3,004

949

468

-1,049

1,625

-185

-192

-1,302

1,469

869

-855

-300

1,195

946

-494

-1,360

2,590

-118

-697

705

Accrued expenses and other liabilities

4,483

12,461

5,375

-6,643

6,497

6,083

7,402

-6,576

3,848

7,048

-738

-2,436

11,183

7,883

4,109

-952

9,388

3,306

-611

-2,063

6,650

3,093

-2,813

-919

1,834

2,082

419

-2,397

1,691

2,179

1,211

-2,024

1,593

1,726

794

-5,443

225

1,591

958

-2,169

Deferred revenue

30

-226

3,216

-233

1,344

1,090

1,926

-2,852

3,160

1,202

871

-853

1,480

-65

509

-179

1,843

114

-1,067

828

453

852

569

435

412

209

144

-206

1,102

202

207

-333

1,134

74

112

-270

-27

471

160

78

Net cash provided by operating activities

86,593

89,440

74,259

64,628

70,391

74,615

60,560

46,631

56,399

56,696

43,157

36,294

37,255

34,125

17,356

26,380

22,557

25,382

17,942

10,914

18,263

15,125

6,712

3,190

9,895

8,449

5,155

-33

7,558

7,709

6,814

4,318

4,993

4,931

2,266

-8,556

146

5,863

-1,788

-2,647

Investing activities:
Purchases of marketable securities

119,767

223,028

144,418

124,067

119,857

128,789

88,254

24,702

115,574

77,900

58,308

73,626

100,910

43,356

66,917

67,318

71,380

90,593

56,341

42,661

25,247

27,491

20,396

24,524

28,696

24,481

18,448

15,401

25,177

5,502

7,250

11,500

7,500

9,001

3,000

5,001

1,501

5,001

1

1,501

Proceeds from the sale and maturity of marketable securities and other

140,332

147,575

169,701

93,180

104,937

90,105

61,062

75,782

58,814

52,679

28,794

66,622

60,812

27,985

69,595

47,090

49,444

68,742

51,190

50,263

13,640

10,000

12,160

35,730

16,001

26,514

8,000

17,750

21,500

15,000

0

5,500

750

0

2,500

4,500

2,000

0

1,000

4,000

Purchases of other investments and intangible assets

58

13,099

5,000

2,800

12,299

19,010

10,260

1,166

-

-

-

400

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

750

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the sale of WorldHeart common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

217

239

Purchases of property and equipment

10,546

8,853

12,357

12,250

8,535

8,124

12,198

15,147

11,695

26,493

7,871

9,804

26,376

13,586

5,354

5,099

7,691

4,514

1,556

1,863

2,956

736

1,116

380

460

1,065

525

711

764

449

1,153

470

-192

800

665

472

750

463

302

289

Net cash used for investing activities

9,961

-97,405

7,926

-45,937

-35,754

-65,818

-49,650

34,767

-68,455

-51,714

-43,385

-17,208

-69,224

-29,106

-2,676

-25,327

-29,627

-26,365

-7,457

5,739

-16,163

-18,727

-25,799

10,826

-13,155

968

-10,973

888

-4,441

9,049

-8,403

-6,470

-6,558

-8,784

-1,165

-973

-251

-5,464

914

2,449

Financing activities:
Proceeds from the exercise of stock options

500

500

1,400

1,300

1,857

430

4,815

5,798

1,674

2,369

1,702

3,555

2,395

2,501

2,994

2,770

1,534

266

3,382

4,589

2,303

6,064

1,740

820

1,133

2,909

3,387

1,931

197

246

1,265

1,228

2,574

3,883

171

7,629

645

73

249

94

Taxes paid related to net share settlement upon vesting of stock awards

80

401

670

40,536

563

1,547

2,068

67,598

457

623

1,432

17,805

207

290

4,575

15,033

3,405

98

345

3,465

1,792

0

0

1,013

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Excess tax benefit from stock-based awards

-

-

-

-

-

-

-

-

-

-

-

-

7,443

964

2,590

1,041

3,079

105

302

81

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the issuance of stock under employee stock purchase plan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

684

0

446

5

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Principal payments on capital lease obligation

-

-

-

-

-

-

-

-

0

140

193

184

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments in lieu of issuance of common stock for minimum payroll taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-426

-

0

0

-238

-

-

-

-

-

-

-

-

Net cash used for financing activities

-21,765

-24,945

-31,729

-39,276

3,019

-1,116

4,122

-61,800

2,551

1,606

1,140

-14,434

10,400

2,994

1,695

-11,222

1,892

273

3,785

1,210

1,515

6,064

2,137

-193

1,519

2,909

3,699

1,505

-3,928

-10,408

1,535

990

2,697

3,986

368

7,629

805

73

402

94

Effect of exchange rate changes on cash

-418

601

-1,225

612

-816

118

62

-1,285

1,978

-622

-346

278

-460

-1,653

60

212

183

-485

-280

167

-692

-467

-307

1

25

186

512

-84

-495

-90

562

-839

-234

-379

-282

220

938

-430

682

-743

Net increase in cash and cash equivalents

74,371

-32,309

49,231

-19,973

36,840

7,799

15,094

18,313

-7,527

5,966

566

4,930

-22,029

6,360

16,435

-9,957

-4,995

-1,195

13,990

18,030

2,923

1,995

-17,257

13,824

-1,716

12,512

-1,607

2,276

-1,306

6,260

508

-2,001

898

-246

1,187

-1,680

1,638

42

210

-847

Supplemental disclosure of cash flow information:
Cash paid for income taxes

2,206

1,130

3,765

2,584

790

970

574

2,956

3,796

261

105

479

670

175

140

420

124

148

302

274

125

791

127

172

218

236

72

798

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest on capital lease obligation

-

-

-

-

-

-

-

-

0

43

129

130

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosure of non-cash investing and financing activities:
Property and equipment in accounts payable and accrued expenses

-337

-511

206

3,619

3,117

271

-1,797

3,196

-498

2,939

-975

1,872

1,975

-93

2,814

996

1,326

75

273

123

-308

-76

362

215

-32

0

6

86

145

12

1

92

453

38

0

44

17

13

-13

31

Right-of-use assets obtained in exchange for lease liabilities

1,054

83

374

14,139

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-